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A B S T R A C T
Purpose: Few studies have been dedicated to assess neurological symptoms in relations to hypoglycemia.
In this study we investigated the association between different levels of hypoglycemia and the
occurrence of epileptic seizures in patients without a prior diagnosis of epilepsy.
Method: A retrospective cross-sectional study.
Results: We identiﬁed 388 individuals from a laboratory database in Swedish regional hospital who had
been found to have a glucose value of 3.5 mM between January and December 2009. Medical records
were reviewed. Hypoglycemia was deﬁned at three different categories: 0–2 mM (40 patients), 2.1–
3 mM (154 patients) and 3.1–3.5 mM (194 patients).
14 patients had disturbance of consciousness including 3 with seizures.
The majority of cases had coma, a generalized tonic–clonic seizure was seen only when s-glucose
dropped below 2.0 mM. Two cases with focal seizure were noted, one at s-glucose 2.0 mM, and one at s-
glucose 3.3 mM.
The absolute risks (95% conﬁdence interval) for havingmajor neurological symptoms at glucose levels
of 2.0 mM were 0.25 (0.13–0.41), 0.02 (0–0.06) at 2.1–3.0 mM and 0.01 (0–0.03) at 3.1–3.5 mM.
Conclusion: Coma is the most common neurological symptom related to hypoglycemia. Epileptic
seizures are rare and not as common as previously assumed.
 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.1. Introduction
Acute symptomatic seizures (ASS) are events occurring in a
close temporal relationship with an acute central nerve system
(CNS) insult that may be metabolic, toxic, structural, infectious, or
inﬂammatory in nature.2 The prognosis after unprovoked seizures
and ASS differs with regard to risk of seizure recurrence and
mortality; therefore, it is essential to deﬁne metabolic conditions
when acute symptomatic seizures might occur.7
Electrolyte abnormalities and other metabolic derangements
have frequently been associated with epileptic seizures.3 The
International League Against Epilepsy (ILAE) has suggested cut-off
values for different laboratory measures of metabolic disorders
when seizures should be considered as acute symptomatic rather
than unprovoked events.1 The proposed cut-off values for* Corresponding author at: Department of Neuroscience, eurology, Uppsala
University, 75185 Uppsala University Hospital, Uppsala, Sweden. Tel.: +46 18 6110120.
E-mail address: imad.halawa@neuro.uu.se (I. Halawa).
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1059-1311/ 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights remetabolic derangement are arbitrary and based on case reports,
and there are no systematic studies except for seizures due to
hyponatremia.6 Erroneous classiﬁcation of a seizure as acute
symptomaticmay delay the diagnosis of an underlying progressive
brain disorder, and it is essential that the cut-off values be
subjected to systematic evaluation.
Hypoglycemia is frequently encountered in daily clinical
practice.5 We evaluated the risk of seizures at different levels of
hypoglycemia in a retrospective cross-sectional study.
2. Materials and methods
2.1. Design and setting
The study design was a retrospective cross-sectional observa-
tional cohort study. The study was performed at Uppsala
University Hospital, which is an academic care center serving a
primary population of approximately 300 000 people with
59 151 patient admissions per year. Serum glucose levels are
analyzed as part of routine hospital procedures and stored in theserved.
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Hospital. The study was approved by the central ethics committee
in Sweden, and the need for informed consent was waived.
2.2. Patient and data collection
We performed a search for all patients with blood glucose
values of 3.5 mM from the laboratory database between January
and December 2009. The inclusion criteria were patients who had
been admitted to the hospital for further evaluation. Exclusion
criteria were insufﬁcient or inaccessible medical records and a
history of epilepsy or documented non-metabolic risk factors for
acute symptomatic seizures (e.g., stroke, CNS infection, traumatic
brain injury, anoxic encephalopathy or other active lesion in the
CNS). For each case, a search was performed for the corresponding
medical records. The medical records were carefully inspected for
information on demographic and clinical variables including
seizures or other disturbances of consciousness within 24 h of
the sampling time.2 The variables collected for the study included
the following: age, gender, documented co-morbidities, seizure
type and other abnormal hematologic-biochemical analyses when
available (e.g., sodium, urea, creatinine, calcium, magnesium and,
ammonia). The data were anonymized prior to analysis.
Hypoglycemia was classiﬁed according to the following three
categories according to the ILAE cut-off values: serum glucose 0–
2 mM, 2.1–3 mM and 3.1–3.5 mM.
388 patients with hypoglycemia were included, 40 in the 0–
2 mM and 154 in the 2.1–3 mM category. In the 3.1–3.5 mM
category, 194 patients were randomly selected out of 486 patients
who were within that range. In cases of multiple sampling of the
same patient, we included only the lowest serum glucose level;
therefore, each patient could only have one serum glucose level in
the study. In cases ofmultiple hospital admissions during the study
period, only the lowest serum glucose level was included.Table 1
Clinical characteristics of patients with hypoglycemia and neurological symptoms.
s-Glucose Age Sex Symptoms Other derangement
0.7 71 F Coma High creatinine
1.1 53 M Coma
1.2 70 M GTCS High bilirubin and ammo
1.2 86 F Coma
1.3 87 F Coma Hypocalcemia
1.6 82 M Coma High creatinine
1.8 33 M Coma
2.0 20 M CPS
2.0 79 F Coma
2.0 61 F Coma High creatinine
2.1 27 M Coma
2.1 63 M Coma High creatinine
2.2 80 F Coma
3.3 85 M CPS
Abbreviations: CPS, complex partial seizure; DM, diabetes mellitus; GE, gastroenteritis;
drugs.2.3. Statistical analysis
The absolute risk for each serum glucose category was
estimated by dividing the number of patients with hypoglycemia
by the total number of exposed individuals.
The logistic analysis was performed using SAS 9.3, and the
Clopper–Pearson method was used to calculate the 95% exact
conﬁdence interval.
3. Results
In total, 388 patients were included in the study. Fourteen
patients had disturbances of consciousness including three with
seizures (see Table 1).
Most cases were in the category of 0–2 mM glucose. The
majority of cases had coma, a generalized tonic–clonic seizure was
only observed when the s-glucose dropped below 2.0 mM
(1.2 mM). Two cases with focal seizure were noted: one patient
had an s-glucose level of 2.0 mM, and the other patient 3.3 mM.
The mean age of patients with neuroglycemic symptoms was
54 years (range 20–87 years), and themean age of patientswithout
neuroglycemic symptoms was 64 years (range 2–95 years).
Twelve out of fourteen patients with neurological symptoms
had diabetes mellitus and were treated with insulin alone or in
combination with oral antidiabetic drugs.
Co-morbidity with alcoholism, severe illness such as nephrop-
athy and terminal prostate cancer were contributing factors in the
patients with seizures.
For details on the clinical characteristics, see Table 1.
The absolute risk for developing neurological hypoglycemic
symptoms, including coma and seizures was highest in the
category 0–2.0 mM (0.25 CI (13–0.41)) (Table 2.).
The absolute risks were 0.02 CI (0–0.06) in the category 2.1–
3 mM and 0.01 (0–0.03) in the category 3.1–3.5 mM.Possible cause Co-morbidity Outcome
DM2
GE, OAD
Nephropathy Recovered
DM2
Insulin-treated
Alcoholism Recovered
nia DM2, OAD Alcoholism,
Hypertension
Nephropathy
Recovered
DM2
OAD
Recovered
DM2. GE
OAD
Recovered
DM2
OAD
Nephropathy Recovered
DM1
Insulin-treated
Recovered
DM1
Insulin -treated
Cannabis addiction Recovered
DM2, OAD
Insulin -treated
Nephropathy Recovered
Sepsis Nephropathy
Hepatitis C
Death
Anorexia Recovered
DM2, OAD Hypertension Recovered
DM2
Insulin -treated
Hypertension Recovered
DM2
Insulin-treated
Prostate cancer (Advanced) Recovered
GTCS, generalized tonic–clonic seizures; M, male; F, female; OAD, oral antidiabetic
Table 2
Absolute risk with 95% conﬁdence interval (CI) for neurological symptoms at different s-glucose levels.
Category (mM) Patients without
symptoms (nr)
Patients with neurological
symptoms (nr)
Total patients (nr) Absolute risk Conﬁdence interval
(Clopper–Pearson)
0–2.0 30 10 40 0.25 0.13–0.41
2.1–3.0 151 3 154 0.02 0–0.06
3.1–3.5 193 1 194 0.01 0–0.03
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This study is the ﬁrst systematic attempt to evaluate the risk of
acute symptomatic seizures based on different levels of hypogly-
cemia. An acute neuroglycopenic symptom is a direct result of
brain glucose deprivation and includes cognitive impairment,
behavioral changes, psychomotor abnormalities, seizures and
coma.4
Although it is recognized that hypoglycemia may cause
neurological symptoms, only limited epidemiological data are
available on the relationship between the incidence of seizures and
hypoglycemia. In one study in an emergency department,
125 patients were identiﬁed with symptomatic hypoglycemia.
The majority of the cases had impairment of consciousness, and
only 9 cases with seizures were recognized. Of these, 3 had known
epilepsy, and the remaining cases were related to alcoholism.8 This
is in line with our results, which indicate that coma is the
dominating neurological symptom in hypoglycemia and seizures
are rare manifestation. Among our patients, only one generalized
tonic–clonic seizure and two focal seizureswere recorded. The case
with a generalized seizure was related to a glucose level below
2.0 mM, and other aggravating circumstances such as alcoholism
and additional metabolic derangement may have had some
impact.
From textbooks and general overviews we are taught that there
are many causes of ASS and electrolytic and metabolic disorders
are believed to account for 9%.1 How many of these cases that can
be attributed to hypoglycemia are not known. From this study it is
not possible to estimate the incidence of seizures induced by
hypoglycemia. The risk of seizures at different blood glucose levels
however, seems to be low.
This study was performed using a systematic unbiased
approach with a large database. However, the retrospective nature
of the study is an important limitation. The observations are based
on a retrospective chart review, and we have not been able to
conﬁrm the accuracy of the neurological symptoms. The symptoms
may also have been instigated or aggravated by co-morbidities and
other metabolic disturbances. In addition, more subtle seizures
may have been missed because they would have required an EEG
for diagnosis. The study was performed in a single center, which
may limit its generalizability. The number of cases with seizures is
small, and the CIs of the estimates are wide and partiallyoverlapping. Importantly, the analysis could provide associations,
although inference regarding causality cannot be drawn.
Notwithstanding the limitations, in this study of a large number
of patients with hypoglycemia, a notably low frequency of seizures
was noticed. This indicates that the risk of seizures in association
with low blood glucose levels seems to be low. This is a ﬁnding of
potentially great clinical relevance, since seizures in the presence
of hypoglycemia are often presumed to be acute symptomatic.
Should our ﬁndings be validated, a more thorough work-up of
patients presenting with seizures in the presence of hypoglycemia,
especially at moderate levels, might be warranted. Future large
prospective studies will hopefully be useful in predicting a more
precise risk estimate for seizures related to hypoglycemia.
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